基于两组科学家的数据，GLP-1开始看起来具有治疗糖尿病的潜力。为了验证这一潜力，他们决定进行更多的试验，包括在人体中应用GLP-1。1987年夏天，丹麦的团队领导人参加了一次与当时在汉默史密斯医院工作的内分泌学家斯蒂芬·布卢姆（Stephen Bloom）举行的派对。在派对上，他们讨论了GLP-1的治疗潜力。不过很快，研究走向...
未来,这或许将成为GLP-1药物发展的全新风口。 参考资料: GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next? Deep Science预印本
[9] Best selling drugs of 2023. iPharmaCenter. 2023 Nov 3. [10] Kalra S, et al. A Review on Semaglutide: An Oral Glucagon-Like Peptide 1 Receptor Agonist in Management of Type 2 Diabetes Mellitus. Diabetes Ther. 2020 Sep;11(9):1965-1982. [11] Chao AM, et al. Semaglutide for the...
Given the past decade’s dramatic increase in glucagon-like peptide-1 receptor agonist (GLP-1 RA) use among people with type 2 diabetes, clinicians have raised concerns about whether the drugs, which target reward areas in the brain, could lead to suicidal thoughts. A new study in the ...
[3]https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Accessed [4] Andersen, A., F.K. Knop and T. Vilsbøll, A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. Drugs, 2021. https...
图8. 大多数人认为医保应为超重人群支付GLP-1类药物的减重费用 原文链接:https://www.kff.org/health-costs/poll-finding/kff-health-tracking-poll-may-2024-the-publics-use-and-views-of-glp-1-drugs/ 最新《国际糖尿病》读者专属...
如果说既有扎实的科学基础,同时在临床上有神奇的疗效,就有可能获得诺奖,那GLP-1药物有没有可能? 答案是肯定的。 这些GLP-1药物在生活中随处可见——帮助人们控制糖尿病,并有望降低患心血管疾病的风险,甚至有一天可以治疗药物和酒精成瘾。
First the drugs tackled diabetes. Then, with just an injection a week, they took on obesity. Now they are being found to treat cardiovascular and kidney disease, and are being tested for Alzheimer’s and addiction. It is early days yet, but GLP-1 receptor agonists have all the makings ...
Diabetes and Obesity: A Phase 2 Randomized Clinical Trial. JAMA Netw Open. 2021 Jan 4;4(1):e2033457. doi: 10.1001/jamanetworkopen.2020.33457. Erratum in: JAMA Netw Open. 2021 Feb 1;4(2):e211376. Erratum in: JAMA Netw Open. 2021 Mar 1;4(3):e212581. PMID: 33439265; PMCID: PMC...